In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy.
Yinwen ChengCaitlin D Lemke-MiltnerWattawan WongpattaraworakulZhaoming WangCarlos H F ChanAliasger K SalemGeorge J WeinerAndrean Llewela Simons-BurnettPublished in: Journal for immunotherapy of cancer (2021)
These results demonstrate that in situ vaccination with CMP-001 can induce both local and abscopal antitumor immune responses. Additionally, the antitumor efficacy of CMP-001 combined with α-PD-1 therapy warrants further study as a novel immunotherapeutic strategy for the treatment of HNSCC.